Всероссийский научно-исследовательский институт физиологии, биохимии и питания животных – филиал Федерального государственного бюджетного научного учреждения «Федеральный научный центр животноводства – ВИЖ имени академика Л.К. Эрнста»
ABSTRACT. On the basis of literature data and the results of their own research in production of transgene animals, the works were analyzed made in the field of obtaining transgenic mice with integrated human genes of N-acetyltransferase (Nat1 and Nat2) for using as the biomodels in the pharmacological and toxicological research. The analysis was performed of the possible causes of failures in the producing transgenic mice with increased expression of human genes Nat1 and Nat2 and with ability to transfer the transgenes to offspring. The importance of the role of promoters in creating genetically engineered constructs is discussed. The data are presented that for generating transgenic animals by microinjection of gene constructs into pronuclei, different variants of cytomegalovirus promoter are ineffective, since this promoters begin to initiate uncontrolled expression of the transgene during very early stages of embryonic development, which often leads to death of the embryo. The possibility is suggested of obtaining lines of humanized mice with integrated human genes Nat1 and Nat2 and reduced activity of endogenous Nat2 without the use of mice knockout own genes Nat1 and Nat2 for crossing with transgenic mice.
REFERENCES
1. Boukouvala S., Sim E. Expression of murine NAT genes in early development. In: IUBS Birmingham, 7, 2000.
2. Cao W., Chau B., Hunter R., Strnatka D., McQueen C.A., Erickson R.P. Only low levels of exogenous Nacetyltransferase can be achieved in transgenic mice. Pharmacogen. J. 2005, 5: 255-261.
3. Cao W., Strnatka D., McQueen C.A., Hunter R.J., Erickson R.P. N-Acetyltransferase 2 activity and folate levels. Life Sci. 2010, 86: 103-106.
4. Chan A.W.S., Homan E.J., Ballou L.U., Burns J.C., Bremel R.D. Transgenic cattle produced by reverse-transcribed gene transfer in oocytes. Proс. Natl. Acad. Sci. USA. 1998. 95: 14028-14033.
5. Clark A.J., Simons J.P., Wilmut I., Lathe R. Pharmaceuticals from transgenic livestock. Trends Biotech. 1987, 5: 20-24.
6. Cribb A.E., Grant D.M., Millar M.A., Speilberg S.P. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J. Pharmacol. Exp. Ther. 1991. 259: 1241-1246.
7. Doll M.A., Zang Y., Moeller T., and Hein D.W. Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes. J. Pharmacol. Exp. Ther. 2010, 334: 540-544.
8. Erickson R., Morgan C., McQueen C.A. In: 2nd International NAT Workshop. Eynsham, Oxford, 2000, Abstract No. 1.
9. Estrada-Rodgers L., Levy G.N., Weber W.W. Substrate selectivity of mouse N-acetyltransferases 1, 2 and 3 expressed in COS-1 cell. Drug Metab Disp. 1998, 26: P. 502-505.
10. Ezerskii V.A., Tevkin S.I., Trubitsina T.P., Koloskova E.M., Shishimorova M.S., Bezborodova O.A., Yakubovskaya R.I., Ryabykh V.P. [Integration and expression of tissue specific human lactoferrin gene in mammary gland of transgenic rabbits].Problemy biologii productivnykh zhivotnykh - Problems of Productive Animal Biology. 2013, 4: P. 33-52.
11. Fretland A.J., Doll M.A., Gray K., Feng Y., Hein, D.W. Cloning, sequencing, and recombinant expression of Natl, Nat2, und NatS derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterisation of the activation and deactivation of aromatic amine carcinogens. Toxicol. Appl. Pharmacol. 1997, 142: P. 360-366.
12. Glowinski I.B., Weber W.W. Genetic regulation of aromatic amine N-acetylation in inbred mice. J. Biol. Chem. 1982, 257: 1424-1430.
13. Haskell R.E., Bowen R.A. Efficient production of transgenic cattle by retroviral infection of early embryos. Mol. Reprod. Dev. 1995, 40: 386-390.
14. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xio G.H. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 2000, 9: 29-42.
15. Hickman D., Pope J., Juchau M.R., Namkung M.J., Berry D.L., Zachariah P.K. Oxidative biotransformations of 2-acetylaminofluorenein fetal and placental tissues of humans and monkeys: correlation with arylhydro-carbon hydroxylase activities. Drug Metab. Dispos. 1975, 3: 494-501.
16. Hickman D., Pope J., Patil S.D., Fakis G., Smelt V.M., Stanley L.A., Payton M.A., Unadkat J.D., Sim E. Expression of arylamine N-acetyltransferase in human intestine. Gut. 1998, 42: 402-409.
17. Hughes N.C., Janezic S.A., McQueen K.L., Jewett M.A.S., Castranio T., Bell D.A., Grant D.M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics. 1998, 8: 55-66.
18. Ilett K.F., Ingram D.M., Carpenter D.S., Teitel C.H., Lang N.P., Kadlubar F.F., Minchin R.F. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem. Pharmacol. 1994, 47: 914-917.
19. Iwakura Y., Shioda T., Tosu M. et al. The induction of cataracts byHIV-1 in transgenic mice // AIDS, 1992, 6(10): 1069-1075.
20. Jenne J.W. Partial purification and properties of the isoniazid transacetylase in human liver: its relationship to the acetylation of p-amino-salicylic acid. Clin. Invest. 1965, 44: 992-2002.
21. Johnson N., Troen A., Fernando S., Warren D., Nagy Z., Smith A.D., Sim E. Investigation of W-acetyltransferase (NAT1) in Alzheimer's disease: identification of a novel NAT1 allelic variant. Eurotox. 2000, 9: 59-68.
22. Karkishchenko N.N., Petrova N.V., Slobodenyuk V.V. Biomeditsina – Biomedicine. 2014, 2: 4-16.
23. Kawamura A., Westwood I., Wakefield L., Long H., Zhang N., Redfield C., Sim E. Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochem. Pharmacol. 2008, 75: 1550-1560.
24. King C.M., Land S.J., Jones R.F., Debiec-Rychter M., Lee M.S., Wang C.Y. Role of acetyltransferases in the metabolism and carcinogenicity of aromatic amines. Mutat. Res. 1997, 376: 123-128.
25. Kloth M.T., Gee R.L., Messing E.M., Swaminathan S. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis. 1994, 15: 2781-2787.
26. Lammer E.J., Shaw G.M., Iovannisci D.M., Finnell R.H. Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N- transferase 1 (NAT1), and risk for orofacial clefts. Birth Defects Res. A Clin. Mol. Teratol. 2004, 70: 846-852.
27. Laurence K.M., James N., Miller M.H., Tennant G.B., Campbell H. Double-blind randomized controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br. Med. J. 1981, 282: 1509-1511.
28. Leff M.A., Fretland A.J., Doll M.A., Hein D.W. Novel N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. Biol. Chem. 1999, 274: 34519-34522.
29. Loehle J.A., Cornish V., Wakefield L., Doll M.A., Neale J.R., Zang Y., Sim E., Hein D.W., Martell K.J., Vatsis K.P., Weber W.W. Molecular genetic basis of rapid and slow acetylation in mice. Mol. Pharmacol. − 1991. − Vol. 40. – P. 218-227.
30. McNulty H., McPartlin J., Weir D., Scott J. Folate catabolism is increased during pregnancy in rats. Nutr. 1993, 123: 1089-1093.
31. McPartlin J., Halligan A., Scott J.M., Darling M., Weir, D.G. Accelerated folate breakdown in pregnancy. Lancet. 1993, 341: P. 148-149.
32. Minchin R.F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochemistry. 1995, 307: 1-3.
33. Mitchell M.K., Futsche, B.W., McQueen C.A. Developmental expression of JV-acetyltransferases in C57BI/6 mice. Drug Metab. Disp. 1999, 27: 261-264.
34. MRC. Vitamin Study Research Group. Prevention of neural tube defects: results of the MRC vitamin study. Lancet. 1991, 338: 131-137.
35. Murdoch J.N., Henderson D.J., Doudney, K., Gaston-Massuet C., Phillips H.M., Paternotte C., Arkell, R., Stanier P., Copp A.J. Disruption of scribble (Scrb1) causes severe neural tube defects in the circletail mouse// Hum. Mol. Genet. 2003, 12(2): 87-98.
36. Ohsako S. and Deguchi T. Cloning and expression ofcDNAs for polymorphic and monomorphic arylamine N-acetyltransferases of human liver. J. Biol. Chem. 1990, 265: 4630-4634.
37. Pacific I.G.M., Benicini C., Rane A. Acetyltransferases in humans: development and tissue distribution. Pharmacology. 1986, 32: 283-291.
38. Payton M., Smelt V., Upton A., Sim E. A method for genotyping murine arylamine /V-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Biochem. Pharmacol. 1999, 58: 779-785.
39. Pursel V.G., Pinkert C., Miller K., Campbell R.G., Palmiter R.D., Brinster R.L., Hammer R.E. Genetic engeneering of livestock. Science. 1989, 244: 1281-1288.
40. Risch A., Smelt V., Lane D., Stanley L.A., Van der Slot W., Ward A., Sim E. Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. Pharmacol. Toxicol. 1996, 78: 235-240.
41. Ryabykh V.P., Shishimorova M.S., Trubitsina T.P., Fatkulina O.B., Tevkin S.I., Smetanina I.G. Trudy regional'nogo konkursa nauchnykh proektov RFFI v oblasti estestvennykh nauk (Proc. regional competition of scientific project of Russ. Fond Basic Res. on natural sciences). Kaluga, 2007, 11: 451-471.
42. Sadrieh N., Davis C.D., Snyderwine E.G. N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res. 1996, 56: 2683-2687.
43. Sim E., Pinter K., Mushtaq A., Upton A., Sandy J., Bhakta S. Arylamine N-acetyltransferases: a pharmacogenomics approach to drug metabolism and endogenous function. Biochem. Soc. Trans. 2003, 31: 615-619.
44. Smelt V.A., Upton A., Adjaye J., Payton M.A., Boukouvala S., Johnson S., Mardon H.J., Sim E. Expression of arylamine /N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum. Mol Genet. 2000, 9: 1101-1107.
45. Smelt V.A., Mardon H.J., Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol. Toxicol. 1999, 83: 149-157.
46. Stanley L.A., Mills I.G., Sim E. Localization of polymorphic A'-acetyltransferase (NAT2) in tissues of inbred mice. Pharmacogenetics. 1997, 7: 121-130.
47. Sugamori K., BrennemanD., Grant D.M. Liver-Selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice. Drug Metab. Disp. 2011, 39: 882-890.
48. Sugamori K., Wong S., Gaednigk A., Yu V., Abramovici H., Rozmahel R., Grant D. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double knockout mice. Mol. Pharmacol. 2003, 64: 170-179.
49. Wakefield L., Cornish V., Long H., Griffiths W.J., Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem. Biophys. Res. Commun. 2007, 364: 556-560.
50. Wakefield L., Long H., Lack N., Sim E. Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene. Mamm. Genome. 2007, 18: 270-277.
51. Ward A., Summers M.E., Sim E. Purification of recombinant human N-acetyltransferase type 1 expressed in E.coli and characterisation of its potential role in folate metabolism. Biochem. Pharmacol. 1995, 49: 1759-1767.
52. Weber W.W., Vatsis K.P. Individual variability in p-amino-benzoic acid acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics. 1993, 3: 209-212.
53. Windmill K.F., McKinnon R.A., Zhu X.Y., Gaedigk A., Grant D.M., McManus M.E. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat. Res.1997, 376: 153-160.